1. Home
  2. ADVM vs TRVG Comparison

ADVM vs TRVG Comparison

Compare ADVM & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • TRVG
  • Stock Information
  • Founded
  • ADVM 2006
  • TRVG 2005
  • Country
  • ADVM United States
  • TRVG Germany
  • Employees
  • ADVM N/A
  • TRVG N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • TRVG EDP Services
  • Sector
  • ADVM Health Care
  • TRVG Technology
  • Exchange
  • ADVM Nasdaq
  • TRVG Nasdaq
  • Market Cap
  • ADVM 47.4M
  • TRVG 306.5M
  • IPO Year
  • ADVM 2014
  • TRVG N/A
  • Fundamental
  • Price
  • ADVM $2.54
  • TRVG $3.64
  • Analyst Decision
  • ADVM Strong Buy
  • TRVG Buy
  • Analyst Count
  • ADVM 5
  • TRVG 4
  • Target Price
  • ADVM $23.80
  • TRVG $4.88
  • AVG Volume (30 Days)
  • ADVM 312.5K
  • TRVG 56.8K
  • Earning Date
  • ADVM 08-11-2025
  • TRVG 07-29-2025
  • Dividend Yield
  • ADVM N/A
  • TRVG N/A
  • EPS Growth
  • ADVM N/A
  • TRVG N/A
  • EPS
  • ADVM N/A
  • TRVG N/A
  • Revenue
  • ADVM $1,000,000.00
  • TRVG $522,618,892.00
  • Revenue This Year
  • ADVM N/A
  • TRVG $17.11
  • Revenue Next Year
  • ADVM $18.82
  • TRVG $10.28
  • P/E Ratio
  • ADVM N/A
  • TRVG N/A
  • Revenue Growth
  • ADVM N/A
  • TRVG 1.70
  • 52 Week Low
  • ADVM $1.78
  • TRVG $1.60
  • 52 Week High
  • ADVM $10.14
  • TRVG $5.83
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 51.83
  • TRVG 42.97
  • Support Level
  • ADVM $2.19
  • TRVG $3.55
  • Resistance Level
  • ADVM $2.75
  • TRVG $3.97
  • Average True Range (ATR)
  • ADVM 0.22
  • TRVG 0.17
  • MACD
  • ADVM 0.04
  • TRVG 0.00
  • Stochastic Oscillator
  • ADVM 64.06
  • TRVG 33.33

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.

Share on Social Networks: